BPIFB6

Model summary

A secreted human lipid-binding glycoprotein that uses a bilobal BPI/LBP fold to capture and transfer phospholipids and sterols in extracellular fluids and vesicles. By scavenging inflammatory lipids and modulating membrane composition, it dampens cytokine production and restrains macrophage activation. Its soluble nature and association with extracellular vesicles position it as an extracellular lipid shuttle that tempers inflammatory signaling through membrane-interfacial lipid exchange.

Predicted Gene Ontology terms

1. 01

   I begin with the InterPro architecture.

   The sequence is globally assigned to IPR051660 (BPI fold-containing BPI/LBP family, residues 1–451), indicating a two-lobed BPI/LBP scaffold specialized for lipid binding and transfer. The N-terminal lobe is defined by IPR017942 (Lipid-binding serum glycoprotein, N-terminal domain, residues 22–182), and this region is further captured by IPR017943 (Bactericidal permeability-increasing protein alpha/beta domain superfamily, residues 58–214). The C-terminal lobe is specified by IPR001124 (Lipid-binding serum glycoprotein, C-terminal domain, residues 250–450) and again encompassed by IPR017943 (alpha/beta domain superfamily, residues 216–452). This ordered N- then C-terminal arrangement creates a bilobal, amphipathic alpha/beta fold that forms deep hydrophobic cavities and surface grooves optimized for neutral lipid and phospholipid capture and release. Such a tandem BPI/LBP architecture causes high-affinity lipid binding and interfacial lipid transfer.

2. 02

   From this architecture, the molecular function follows directly.

   The bilobal BPI/LBP fold generates high-specificity pockets that bind membrane lipids and sterols, supporting GO:0008289 lipid binding. The hydrophobic cavities and amphipathic surfaces of both lobes explain selective interactions with phosphatidylcholine, consistent with GO:0031210 phosphatidylcholine binding. The same fold underlies carrier-like behavior—extracting and shuttling lipids between membranes and aqueous environments—which accounts for GO:0005548 phospholipid transporter activity and GO:0120015 sterol transfer activity. The presence of cholesterol-binding grooves in the BPI/LBP family supports GO:0015485 cholesterol binding. Together, these features define a soluble lipid-binding and transfer module rather than an enzyme.

3. 03

   This molecular activity propagates to immune modulation.

   By sequestering and redistributing phospholipids and sterols, the protein dampens membrane-driven inflammatory signaling and reactive oxygen species production in myeloid cells. Such lipid scavenging and neutralization of endotoxin-like mediators causally suppress cytokine output, aligning with GO:0032715 negative regulation of interleukin-6 production, GO:0032717 negative regulation of interleukin-8 production, and GO:0032720 negative regulation of tumor necrosis factor production. Through lipid-handling and signaling attenuation, it restrains effector states in innate immune cells, matching GO:0043030 regulation of macrophage activation.

4. 04

   The cellular context is dictated by secretion and vesicular trafficking.

   The absence of transmembrane segments and the presence of a secreted signal peptide (implied by secretion) place the protein in the extracellular milieu, consistent with a soluble carrier that operates in plasma and interstitial fluids. Its packaging into extracellular vesicles is supported by its soluble, adhesive nature and association with lipid-rich vesicles, aligning with GO:0070062 extracellular exosome. Thus, the architecture and secretion together position the protein in the extracellular space and exosome cargo.

5. 05

   Mechanistically, I hypothesize that the N-terminal lobe initiates high-affinity capture of phosphatidylcholine and sterols at membrane interfaces, while the C-terminal lobe stabilizes lipid complexes and mediates transfer to extracellular acceptors or vesicles.

   By buffering inflammatory lipid mediators and sterol composition in myeloid membranes, the protein reduces assembly and activity of signaling platforms that drive TNF and IL-8 production. Likely interaction partners include extracellular vesicle tetraspanins (e.g., CD9/CD63/CD81) that scaffold exosome cargo loading, lipoprotein particles such as apolipoprotein-containing HDL/LDL that accept transferred lipids, and cell-surface scavenger receptors on macrophages that coordinate lipid exchange. These associations would collectively channel lipids away from pro-inflammatory pathways and toward storage or clearance routes, thereby enforcing the observed immunomodulatory profile.